By Henry Haiser, PhD, Corundum Systems Biology
GLP-1-based medicines have transformed the treatment of obesity and type 2 diabetes, with benefits that now extend well beyond metabolic disease.1 The gut microbiome has long been linked to appetite, metabolism, and obesity, including pathways that influence the body’s own GLP-1 signaling. That overlap raises an important question: where can microbiome interventions add value in a therapeutic landscape increasingly shaped by highly effective GLP-1-based drugs?
The clearest opportunities may lie in the problems that GLP-1-based treatment does not fully solve. Could a microbiome-directed intervention help patients tolerate treatment? Could it support nutrition or the preservation of lean mass during rapid weight loss? And when treatment is reduced or stopped, could it help people maintain the benefits? The evidence is still early, but each of these is a clinical question that can be tested directly.
The Microbiome and GLP-1 Signaling
The best-known GLP-1-based medicines include semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. They produce sustained signaling through pathways that the body normally activates only briefly after eating. Native GLP-1 is released after a meal and then broken down within minutes by an enzyme called DPP-4. The medicines are engineered to resist rapid breakdown and remain active much longer.1
That distinction matters for the microbiome. Most of the microbial mechanisms described below concern the body’s own, or endogenous, GLP-1 system. They show that gut microbes can influence the hormonal environment upstream of drug therapy. Whether manipulating those pathways can meaningfully alter a patient’s response to long-acting GLP-1-based medicines remains unknown.
When gut bacteria ferment dietary fiber, they produce short-chain fatty acids such as butyrate and propionate. These metabolites can stimulate hormone-producing cells in the intestinal wall to release GLP-1. Microbes also transform bile acids into molecules that activate another pathway promoting GLP-1 release.2
Microbial effects can also work in the other direction. Some gut bacteria, particularly Bacteroides species, produce enzymes with DPP-4-like activity that can degrade native GLP-1. The finding adds another layer to the relationship between microbes and host metabolism, although its clinical importance in humans remains uncertain.3
Do GLP-1 Drugs Change the Microbiome?
Studies suggest that the microbiome does change during GLP-1 treatment, but the pattern is inconsistent. Researchers have reported shifts in organisms including Akkermansia muciniphila, while findings on overall microbial diversity vary across studies.2,4,5
The harder question is why those changes occur. Starting a GLP-1-based medicine usually changes how much a person eats, what they choose to eat and how quickly they lose weight. Each of those changes can alter the gut microbiome. As a result, a microbial shift observed after treatment does not by itself show that the drug acted directly on the microbiome or that the shift contributed meaningfully to weight loss. Human evidence for such a causal link remains limited and is further complicated by the fact that many studies have been conducted in people with type 2 diabetes, often receiving metformin, which itself can alter the gut microbiome.2,4,5
Where a Microbiome Intervention Could Matter
Two points in the treatment journey deserve particular attention.
The first is during active treatment. Nausea, constipation and reduced food intake can make GLP-1 therapy harder to tolerate and can complicate nutrition. Fiber-based or microbiome-directed approaches may help with bowel function or gastrointestinal symptoms, but controlled trials in people taking GLP-1-based medicines are still needed.5,6
Claims about nutrient absorption, lean-mass preservation or improved drug efficacy require stronger evidence. Those questions should be tested with clinical endpoints such as symptoms, treatment persistence, body composition, dietary intake and nutrient status. A change in microbial composition alone cannot establish a patient benefit.
The second point is what happens after treatment. Weight regain is common when GLP-1 therapy is discontinued, creating an obvious need for approaches that help sustain metabolic improvements.6 No microbiome intervention has yet been shown to prevent weight regain specifically after GLP-1 discontinuation. A recent study of weight maintenance after diet-induced weight loss nevertheless provides a useful human signal.
A Human Proof-of-Concept
In a 2026 randomized trial, 90 adults classified as overweight or obese completed an eight-week low-energy diet. Those who lost at least 8% of their body weight were then randomized to receive pasteurized A. muciniphila or placebo for 24 weeks while following an unrestricted healthy diet. Participants receiving A. muciniphila regained an average of 1.2 kg, compared with 3.2 kg in the placebo group.7
The result is encouraging, but its boundaries are important. The study was relatively short and followed diet-induced weight loss rather than GLP-1 discontinuation. It therefore supports the idea that a defined microbial intervention can influence weight maintenance in humans; a post-GLP-1 use case still needs to be tested directly.
The fact that the preparation was pasteurized also makes the study mechanistically interesting. Earlier preclinical work identified a heat-stable outer-membrane protein from A. muciniphila that can activate an immune receptor and strengthen the intestinal barrier. A stronger barrier could reduce the passage of bacterial products such as lipopolysaccharide into circulation and dampen low-grade inflammation associated with metabolic dysfunction.8 This pathway has not been proven to explain the weight-maintenance result in humans, but it gives researchers a defined mechanism to investigate.
The trial also produced an exploratory clue about patient selection. Baseline Akkermansia abundance was associated with cardiometabolic response. That finding requires prospective confirmation, but it raises a testable possibility: microbiome biomarkers may eventually help identify the patients most likely to benefit from a particular intervention.7
What It Will Take to Show Clinical Value for Microbiome Interventions
The next studies should start with a specific clinical question. An adjunct used during GLP-1 treatment could be evaluated for gastrointestinal tolerability, treatment persistence, nutrient status or lean-mass preservation. A maintenance intervention could be introduced as treatment is reduced or stopped and tested for weight regain, body composition and metabolic health. A biomarker-guided product would need prospective validation in the subgroup it is designed to serve.
This sets a higher bar for microbiome products in obesity care. A change in microbial composition can provide useful mechanistic information, but the decisive question is whether patients do better. The Akkermansia study offers an early example of a stronger evidence package: a defined microbial preparation, a mechanism that can be investigated and a measurable human outcome.
GLP-1-based medicines have raised the bar for every new obesity intervention. For microbiome products, a shift in bacterial abundance will not be enough; they will have to improve something patients and clinicians care about. Tolerability, nutrition, lean mass and weight maintenance are all reasonable places to look. The crucial next step is to test those ideas in people actually taking or coming off GLP-1-based therapy.
References
1. Drucker, D. J. GLP-1-based therapies for diabetes, obesity and beyond. Nat. Rev. Drug Discov. 24, 631-650 (2025).
2. Kamath, S., Chan, N. S. L. & Joyce, P. GLP-1 agonists and the gut microbiome: A bidirectional relationship. Br. J. Clin. Pharmacol. 92, 1309-1325 (2026).
3. Wang, K. et al. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science 381, eadd5787 (2023).
4. Gofron, K. K., Wasilewski, A. & Malgorzewicz, S. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients 17, 1303 (2025).
5. Johnson, A. J. et al. The potential for complex interplay between GLP-1 receptor agonists, gut microbiome, and obesity management. Can. J. Physiol. Pharmacol. 104, 1-8 (2026).
6. Wang, Y. et al. Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Converging Mechanisms, Interactions, and Strategies for Durable Weight Control. Adv. Nutr. 17, 100647 (2026).
7. Mount, S. et al. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nat. Med. 32, 2107-2116 (2026).
8. Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107-113 (2017).
